A resource for informing patients and caregivers about Multiple Sclerosis, its possible causes, effects, and treatments. Get the most current information on new developments, clinical trials and other important matters for anyone dealing with MS.
Thursday, November 30, 2006
Weekly Monitor Drug and Diagnostic Development in Neurodegenerative Diseases
HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, recently launched Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence Weekly
Courbevoie, France, November 30, 2006 --(PR.COM)-- HiTIS – life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, added recently a neurodegenerative diseases therapies-focused publication to its growing family of periodical competitive intelligence reports.
Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence is a weekly publication reporting industry and academy news in a digital format. The reports cover the whole life cycle of drugs and diagnostics addressing those diseases, from lab-bench to patients, via regulatory authorities.
Drugs and diagnostics (existing and candidates) which are monitored address most frequent neurodegenerative diseases (Alzheimer, Parkinson, Multiple Sclerosis, Huntington, Amyotrophic Lateral Sclerosis) as well as rare disorders (eg. Batten, Menkes, Pick, Sandhoff, Adrenomyeloneuropathy etc.).
“What we are looking for with these publications is to provide pharma, biopharma, biotech and diagnostics industry decision-makers with a unique, synthetic and global source of competitive intelligence data. Time is money, and costs associated with the collection of this information can be tremendous,” said Christian Girard.
He added, “Our news center daily collects, filters, sorts and saves industry and academy primary information, avoiding press redundancy and delays. The publications are derived products. Each report is divided into several parts, following the homepage introducing mentioned companies and institutions: All News, Regulatory, Research, Preclinical, Clinical, Products, Funding, Financial, Deals, Litigation and IP. Links to companies’ websites and full-text releases are included.”
A recent issue of this publication can be viewed at:
http://www.txpreview.com/NCI%20Weekly%20-%20%20Y2006%20W43.htm
About HiTIS Competitive Intelligence Publications
HiTIS Competitive Intelligence Publications family includes several focused electronic publications covering therapeutic fields or technologies, like:
Vaccines Competitive Intelligence Weekly, Neurodegenerative Diseases Tx/Dx Competitive Intelligence Weekly, and Eye Therapies Competitive Intelligence Weekly.
Other similar publications will be announced in due time. Note that specific, customized publications may be developed upon request.
About HiTIS - life science & biotech intelligence
HiTIS - life science & biotech intelligence is a European competitive intelligence firm offering various intelligence resources and tools: a web-based competitive intelligence platform, customized R&D Pipelines, and a series of periodical competitive intelligence publications.
A free of charge 7-day news center trial and reports samples are available on request: see www.txpreview.com for more information
Contact
Christian Girard
Founding Partner & Editor
Mobile +33 (0)6 67 26 60 92
Office +33 (0)1 47 88 23 48
christian.girard@biotech-intelligence.com
www.biotech-intelligence.com and www.txpreview.com
HiTIS - life science & biotech intelligence
11, rue Madiraa - 92400 Courbevoie - France
###
Contact Information
HiTIS - life science & biotech intelligence
Christian Girard
33 147 882 348
christian.girard@biotech-intelligence.com
www.txpreview.com